Latanoprost in the treatment of @entity726 and XXXX .

@entity1 @entity227 @entity1538 @entity267 @entity6839 @entity726 @entity1103 @entity2790 @entity3774
Latanoprost (Xalatan) is a @entity3774 analog prodrug which is activated when hydrolyzed in the @entity267 and plasma. Latanoprost reduces the intraocular pressure (IOP) by increasing uveoscleral outflow. Other locally applied medications reduce IOP either by increasing the outflow of fluid through the trabecular drainage system or by reducing the production of fluid in the eye. Latanoprost, which is used topically in the eye at the low dose of 0.005% once daily, has been shown in phase III studies carried out in Scandinavia, the U.K. and the U.S. to be capable of lowering the IOP in @entity1 with @entity1538 and @entity2790 by 35%. This low IOP is maintained over at least a 2-year period. Latanaprost is as effective, or possible slightly more effective than @entity6839 in its pressure reducing effects. Additional pressure reduction can be achieved by adding latanoprost to existing @entity726 medications. Because latanoprost is rapidly metabolized outside the eye, systemic side effects do not occur. Increased iris pigmentation occurs in at least 10% of hazel (but not blue or dark-eyed @entity1 ). So far no ocular problem has occurred because of the increased production of pigment which is not released from the iris. Isolated cases of @entity1103 have occurred, so that anyone complaining of @entity227 while using the drug should be fully investigated.
